Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 8/20 | 0.74 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.74 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.74 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.74 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.74 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.74 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.74 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.66 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.66 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1278380 | 1.00 | OPRD1 (0.74) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL29359245 | 1.00 | OPRD1 (0.74) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL678993 | 1.00 | OPRD1 (0.74) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL15249248 | 1.00 | OPRD1 (0.74) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Hydrochloric Acid SCHEMBL31058090 | 0.99 | OPRD1 (0.73) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Propionic Acid SCHEMBL28993771 | 0.95 | OPRD1 (0.67) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL16866229 | 0.95 | OPRM1 (0.66) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL23673341 | 0.91 | OPRD1 (0.71) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL31298539 | 0.91 | OPRM1 (0.76) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL27557540 | 0.90 | OPRD1 (0.67) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6956 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-20250319074-A1 | TREATMENT AND MANAGEMENT OF AUGMENTATION IN RESTLESS LEGS SYNDROME | UNIV EAST CAROLINA (US) | 2025-10-16 | — | — | US | claimed |
| US-20250255781-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-08-14 | — | — | US | claimed |
| US-12383743-B2 | Treatment of addiction and dependency | TACA JR ARTURO C (US) | 2025-08-12 | — | — | US | claimed |
| US-20250228771-A1 | ALKALINE INTRAORAL PRODUCTS | EMPLICURE AB (publ) (SE) | 2025-07-17 | — | — | US | claimed |
| EP-4581017-A1 | NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS | Biodol Therapeutics (FR) | 2025-07-09 | — | — | EP | claimed |
| EP-4565202-A1 | ALKALINE INTRAORAL PRODUCTS | EMPLICURE AB (publ) (SE) | 2025-06-11 | — | — | EP | claimed |
| US-12296043-B2 | Liquisoft capsules | PATHEON SOFTGELS INC. (US) | 2025-05-13 | — | — | US | claimed |
| EP-4510999-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | Bristol-Myers Squibb Company (US) | 2025-02-26 | — | — | EP | claimed |
| WO-2024254056-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | CATALENT ONTARIO LIMITED (CA) | 2024-12-12 | — | — | WO | claimed |
| EP-0914097-A2 | COMPOSITION AND DOSAGE FORM COMPRISING OPIOID ANTAGONIST | ALZA CORPORATION (US) | 1999-05-12 | — | — | EP | claimed |
| US-5866164-A | Composition and dosage form comprising opioid antagonist | ALZA CORPORATION (US) | 1999-02-02 | — | — | US | claimed |
| EP-0785775-A4 | MELT-EXTRUDED ORALLY ADMINISTRABLE OPIOID FORMULATIONS | EURO CELTIQUE SA (LU) | 1998-08-19 | — | — | EP | claimed |
| WO-1997033566-A2 | COMPOSITION AND DOSAGE FORM COMPRISING OPIOID ANTAGONIST | ALZA CORPORATION (US) | 1997-09-18 | — | — | WO | claimed |
| US-5654281-A | Inhibiting the development of tolerance to and/or dependence on an addictive substance | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1997-08-05 | — | — | US | claimed |
| EP-0785775-A1 | MELT-EXTRUDED ORALLY ADMINISTRABLE OPIOID FORMULATIONS | Euroceltique S.A. (LU) | 1997-07-30 | — | — | EP | claimed |
| WO-1996014058-A1 | MELT-EXTRUDED ORALLY ADMINISTRABLE OPIOID FORMULATIONS | EURO-CELTIQUE, S.A. (LU) | 1996-05-17 | — | — | WO | claimed |
| EP-0647448-A1 | Orally administrable opioid formulations having extended duration of effect | Euroceltique S.A. (LU) | 1995-04-12 | — | — | EP | claimed |
| EP-0608893-A1 | Inhibiting the development of tolerance to and/or dependence on an additive substance | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-08-03 | — | — | EP | claimed |
| US-4126684-A | 4-AMINO-3-P-HALOPHENYLBUTYRIC ACIDS AND THEIR DERIVATIVES USED IN THE CONTROL OF NARCOTIC ABUSE | CIBA-GEIGY CORPORATION (US) | 1978-11-21 | — | — | US | claimed |